A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, S. | - |
dc.contributor.author | Lee, M.-H. | - |
dc.contributor.author | Seong, M. | - |
dc.contributor.author | Kim, S.T. | - |
dc.contributor.author | Kang, J.-H. | - |
dc.contributor.author | Cho, B.C. | - |
dc.contributor.author | Lee, K.H. | - |
dc.contributor.author | Cho, E.K. | - |
dc.contributor.author | Sun, J.-M. | - |
dc.contributor.author | Lee, S.-H. | - |
dc.contributor.author | Ahn, J.S. | - |
dc.contributor.author | Park, K. | - |
dc.contributor.author | Ahn, M.-J. | - |
dc.date.available | 2020-10-20T00:59:03Z | - |
dc.date.created | 2020-08-10 | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78313 | - |
dc.description.abstract | Background: Up to 40% of patients with non-small-cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) present with disease progression in the central nervous system (CNS), either as brain metastases (BM) or leptomeningeal metastases (LM). Osimertinib (80 mg), a third-generation, irreversible, oral EGFR TKI, has shown efficacy in active CNS metastases. However, efficacy of osimertinib 160 mg in BM or LM is unclear. Patients and methods: This prospective, single-arm, two cohort study evaluated the efficacy of osimertinib 160 mg in T790M-positive BM or LM NSCLC patients who progressed on prior EGFR TKI (NCT03257124) treatment. The primary end points were objective response rate (ORR) (H1 = 30%) for the BM cohort and overall survival (OS) (H1 = 5 months) for the LM cohort. Results: The median follow-up duration was 10.1 months and 9.6 months for the BM and LM cohorts, respectively. In the BM cohort, intracranial ORR and disease control rate were 55.0% and 77.5%, respectively. The median progression-free survival (PFS) was 7.6 months [95% confidence interval (CI) 5.0–16.6]; the median OS was 16.9 months [95% CI 7.9–not reached (NR)]. In the LM cohort, intracranial disease control rate was 92.5% and complete response rate was 12.5%. The median OS was 13.3 months (95% CI 9.1–NR); the median PFS was 8.0 months (95% CI 7.2–NR). Subgroup analyses based on previous exposure to T790M-targeting agents, including osimertinib 80 mg or other third-generation EGFR TKIs, showed no difference in PFS in both the BM (n = 18, P = 0.39) and LM (n = 17, P = 0.85) cohorts. Previous radiotherapy favored PFS in the BM cohort (hazard ratio 0.42, P = 0.04). The most common adverse events were decreased appetite, diarrhea, and skin rash; however, most were grade 1–2. Conclusion: Thus, osimertinib 160 mg demonstrated promising ORR and survival benefit with a tolerable safety profile in EGFR T790M-positive NSCLC patients with CNS metastasis who progressed on prior EGFR TKIs. © 2020 European Society for Medical Oncology | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.title | A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000574680100016 | - |
dc.identifier.doi | 10.1016/j.annonc.2020.06.017 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, v.31, no.10, pp.1397 - 1404 | - |
dc.identifier.scopusid | 2-s2.0-85088870026 | - |
dc.citation.endPage | 1404 | - |
dc.citation.startPage | 1397 | - |
dc.citation.title | ANNALS OF ONCOLOGY | - |
dc.citation.volume | 31 | - |
dc.citation.number | 10 | - |
dc.contributor.affiliatedAuthor | Cho, E.K. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | brain metastases | - |
dc.subject.keywordAuthor | EGFR T790M | - |
dc.subject.keywordAuthor | leptomeningeal disease | - |
dc.subject.keywordAuthor | non-small-cell lung cancer | - |
dc.subject.keywordAuthor | osimertinib | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.